| Bioactivity | ALX-1393 TFA, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model[1]. |
| Invitro | ALX1393 TFA (i.c.v.; 25, 50, and 100 μg) in normal rats suppresses the late-phase response in the formalin test but does not affect motor performance. ALX1393 inhibits mechanical and cold hyperalgesia in a dose-dependent manner[2]. 0 --> ALX-1393 TFA 相关抗体: |
| Name | ALX-1393 TFA |
| Formula | C25H23F4NO6 |
| Molar Mass | 509.45 |
| Appearance | 固体 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Haranishi Y, et al. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. Anesth Analg. 2010 Feb 1;110(2):615-21. [2]. Takahashi Y, et al. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. Pharmacol Biochem Behav. 2015 Mar;130:46-52. |